INTRODUCTION: Prior retrospective studies found that COVID-19 infection during pregnancy is associated with an increased risk of adverse pregnancy outcomes such as preeclampsia, gestational diabetes, and preterm labor. Our study aims to investigate the risks of adverse pregnancy outcomes associated with COVID-19 infection acquired at least 3 months prior to pregnancy. METHODS: De-identified data was obtained from the TriNetX database. Population was stratified to compare women of childbearing age (15–45 years old) who contracted COVID-19 within 3–12 months prior to pregnancy to women without a history of COVID-19. Outcomes were measured within 1 year of pregnancy diagnosis to assess the effects of COVID-19. Statistical analyses used risk ratios (RRs) and P-values less than .05 to measure significance. RESULTS: This study identified 5,578 patients who contracted COVID-19 3–12 months prior to pregnancy and 970,218 patients without COVID-19 prior to matching for demographics and diagnoses. Cohorts were balanced (n=5,578 per cohort) using (1:1) propensity score matching for age, sex, race/ethnicity. Patients who contracted COVID-19 prior to pregnancy had a higher risk for preeclampsia (RR 1.428; P<.0001), fetal growth restriction (RR 5.613; P<.0001), and antepartum hemorrhage (RR 1.649; P<.0001). Preterm labor, death, and gestational diabetes were not significant. CONCLUSION: Patients who contracted COVID-19 between 3 and 12 months prior to pregnancy have an increased risk for preeclampsia, fetal growth restriction, and antepartum hemorrhage compared to patients without COVID-19. Further investigation is warranted to validate these findings in prospective studies and to guide peripartum care for this population.